Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00420992 · ClinicalTrials.gov registry record · Phase 3
A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 547
- Enrollment target
NCT00420992 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 547 participants.
The verdict
NCT00420992, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 547 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of Kadian NT (ALO-01) compared with placebo for treating moderate to severe chronic pain over a 12 week period.
Interventions
- DRUG Placebo
- DRUG ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 547 participants |
| Start Date | 2006-12 |
| Est. Completion | 2007-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00420992
The ClinicalTrials.gov registry entry for NCT00420992 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 547 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00420992 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00420992 about?
NCT00420992 is a clinical study titled "A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee". The purpose of this study is to evaluate the efficacy of Kadian NT (ALO-01) compared with placebo for treating moderate to severe chronic pain over a 12 week period.
What is the current status of trial NCT00420992?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 547 participants. The study started on 2006-12. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00420992?
The interventions under investigation include: Placebo (DRUG), ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release) (DRUG).
Who is sponsoring clinical trial NCT00420992?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.